Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results
Date:3/10/2011

n the gain on sale of Insmed's follow-on biologics (FOB) assets to Merck in March 2009.  The lower interest expense was due to the reduction of the debt discount amortization associated with the Company's 2005 convertible notes which were fully paid off in 2010.

For the year-ended December 31, 2010, revenues totalled $6.9 million, as compared to $10.4 million for the year-ended December 31, 2009.  The reduction was primarily due to a year-over-year decrease of $2.3 million in cost recovery from Insmed's IPLEX EAP in Europe, a $1.0 million reduction in grant revenue related to the 2009 receipt of a $1.0 million grant from the MDA and $0.1 million in reduced royalties.  The causes of the fourth quarter revenue variance were also responsible for the full-year differences in revenue between 2010 and 2009.

Net loss for the 12-months ended December 31, 2010 was $6.4 million, or $0.49 per share, compared to a net income of $118.4 million, or $9.31 per share, for the corresponding 12-months of 2009.  This $124.8 million variance was due to the $127.0 million after tax gain on the sale of the Company's FOB assets to Merck in 2009, combined with a $3.5 million decrease in total revenues. These were partially offset by a $4.0 million reduction in total expenses, a $1.0 million increase in investment returns and a $0.7 million decrease in interest expense.

The $4.0 million decrease in total expenses was due to a $4.4 million reduction in R&D Expenses, which was partially offset by a $0.4 million increase in SG&A Expenses.  The $4.4 million reduction in R&D Expenses was due primarily to a decrease in manufacturing expenses following the sale of Insmed's FOB assets in March 2009, and was partially offset by the ARIKACE-related R&D Expenses incurred in December 2010.  The $0.4 million increase in SG&A Expenses was due largely to the increased finance, legal and consulting fees related to the strategic review an
'/>"/>

SOURCE Insmed Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Insmed to Host Second Quarter 2009 Conference Call
2. Insmed Announces Addition to the Russell 3000(R) Index
3. Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
4. Insmed CEO Resigns Due to Health Concerns
5. Insmed Announces First Quarter 2009 Financial Results
6. Insmed Regains NASDAQ Compliance
7. Insmed to Host First Quarter 2009 Conference Call
8. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
9. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
10. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
11. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015  VLP Therapeutics, LLC. ... focusing on the research and development of therapeutic and ... a novel and proprietary vaccine technology, today announced that it ... of Tropical Medicine at Nagasaki ... will facilitate VLP,s research and development of dengue vaccine ...
(Date:4/1/2015)... ROCKLAND, Mass. , April 1, 2015  EMD ... Germany , announced today the appointment ... of Medical Affairs, Neurology and Immunology. In this capacity, ... commercial and business development projects and collaborations for Rebif ... Immunology and Neurology pipeline. Dr. Munschauer ...
(Date:4/1/2015)... - Canada,s Research-Based Pharmaceutical Companies (Rx&D) ... report on Cost Drivers of Public Drug Plans in ... report, the rates of change in drug costs have been ... percent in 2012/13 for a number of select public drug ... costs of medicines without considering their overall impact on the ...
(Date:4/1/2015)... April 1, 2015 Synthetic Biologics, Inc. ... for serious infections and diseases, with a focus ... data supporting the development of SYN-004, the Company,s ... (IV) antibiotics within the gastrointestinal (GI) tract and ... for the prevention of C. difficile ...
Breaking Biology Technology:VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 2VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 3EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 2EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 3EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 4EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 5Rx&D responds to PMPRB report: overall impact of medicines must always be considered 2Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 2Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 3Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 4
... Oct. 30 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ) ... chronically infected with hepatitis C virus (HCV) in Part ... both healthy volunteers and,HCV patients. ANA773 is the Company,s ... study, patients in the first cohort will receive,800 mg ...
... press conference,Orange Romania & Medic4all launched Medic4you, the ... is the fundamental value of the quality of ... together the Medic4you service in,Romania," stated Christos Phocas, ... Medic4you is a telemedicine service based on ...
... Pa., Oct. 30 Cephalon, Inc. (Nasdaq:,CEPH) today announced ... be held on,November 5, 2008, will be webcast live ... http://www.cephalon.com ., Cephalon,s senior management will review the ... The,presentations will be delivered on Wednesday, November 5, 2008 ...
Cached Biology Technology:Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients 2Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients 3Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients 4Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients 5Orange and Medic4all Launched the World's First Cellular Tele-Health Service 2Cephalon, Inc. to Webcast Analyst Day 2Cephalon, Inc. to Webcast Analyst Day 3
(Date:3/20/2015)... DUBLIN , Mar. 20, 2015 Research ... announced the addition of the "India Sensors ... their offering. The sensor market is ... through 2020 Consumer electronics, automotive, industrial ... for sensors in the country. In addition, adoption ...
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... a news clip that aired this week on ... . In a segment "The Next Great Thing", ... ,a new way to pay, and ,a really big breakthrough ...
(Date:3/17/2015)... YORK , March 17, 2015  MecklerMedia ... the largest exhibition for service robots ever held ... RoboUniverse takes place on May 11-13, 2015 at ... and exhibitors for the event include: Acorn Product ... Control; EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... (BRONX, NY) -- Three researchers at the Albert Einstein ... Breast Cancer Research Foundation (BCRF). Drs. Thomas Rohan, Susan ... BCRF in its ongoing effort to support the advancement ... BCRFs generosity is its mission, which is to achieve ...
... from biomass for years. Now, with growing dependency on ... fast becoming part of a fuel revolution that could ... are already available at some gas stations. However, their ... volume of ethanol produced. Sources of biomass for biofuel ...
... Katrina on soil quality and agriculture? How can soil help ... biofuels help make America energy independent? These topics and others ... Meetings of the American Society of Agronomy (ASA), Crop Science ... (SSSA) Nov. 4-8, 2007 at the Ernest N. Morial Convention ...
Cached Biology News:Einstein researchers receive grants totaling $700,000 for innovative breast cancer research 2The race for biofuels driving alternative sources of biomass 2Food and environmental sustainability focus of ASA-CSSA-SSSA Annual Meetings 2
... (GST) is commonly used as a fusion ... (1). The GSTTag sequence has been reported ... cases the solubility of its fusion partners. ... form, GSTTag fusion proteins can be purified ...
a1-Antitrypsin (human, alpha-1 AT)...
... The 7500ce meets the demands of the ... high performance from reliable, robust and simple ... detection power in the most challenging sample ... is equally suited to the toughest analytical ...
... Do you need to make your ... transformation efficiency? Take advantage of Lucigen’s unrivalled ... Custom Competent Cell Service offers: ... transformation efficiencies Fast turnaround ...
Biology Products: